PELOBiotech GmbH (Planegg, Germany) has signed an agreement with ReachBio Research Labs (Seattle, WA, USA) giving PELOBiotech exclusive distribution rights to ReachBio’s full product line for the life science research market within Europe.
ReachBio provides research products and contract services (cellPrism® drug development platform) for applications in basic life science research, drug research & development, toxicology and immunology. The company’s main product lines consist of cryopreserved normal human primary cells derived from peripheral blood (including PBMCs), cord blood, bone marrow, as well as ColonyGEL™ methylcellulose-based media for hematopoietic colony-forming cell (CFC) assays.
The extensive ColonyGEL™ semi-solid media product line includes multiple formulations with different cytokine (growth factor) combinations optimized for the growth of a variety of progenitor cells in blood and bone marrow. In the cytokine-optimized, semi-solid environment provided by ColonyGEL™, the different progenitors grow as morphologically distinct three-dimensional colonies that can be identified and scored microscopically. The ColonyGEL™ line-up also includes formulations optimized for different species, including human, mouse, rat, dog and non-human primate. Applications of CFC assays using ColonyGEL™ media include research into normal and abnormal hematological development, leukemia and cancer stem cells, cell therapy, stem cell biology, investigative toxicology, etc.
ReachBio’s line of normal primary human cells includes highly purified cell types from blood that include the various subsets of T lymphocytes, B lymphocytes, natural killer cells and monocytes. It also includes REACHBIO QUALIFIED™ CD34+ stem cells/primitive progenitors purified from cord blood and bone marrow that have been pre-qualified in CFC assays. ReachBio also specializes in providing customized cell isolation services for customers with specific needs such as unique cell types, particular donor background or HLA type, repeat donor cell isolations, and/or customized vial sizes.
“ReachBio Research Labs is extremely happy to have PELOBiotech representing our products and services in Europe,” said Rob Chaney, General Manager and COO at ReachBio. “We have known Peter Frost, one of the founders of PELOBiotech, for many years and have the utmost respect for him and his knowledge of the life science research market within these research-intensive countries. He has already been aiding ReachBio’s sales and business development efforts for our specialized cell biology contract research services in this same territory for the last few years with great results. Having Peter and PELOBiotech now representing our products as well is a great fit and makes perfect sense.”
Said Dr. Peter Frost, CEO of PELOBiotech, “We are delighted to now be distributing ColonyGel™, normal human cell products and promoting the cellPrism® drug development platform. The high quality of these products and services reflects the reputation for quality and value that ReachBio has built regarding both its contract research services and its products. ColonyGEL™ provides researchers performing CFC assays a great alternative to the methylcellulose-based media provided by the leading competitor, which has become quite overpriced through many years of price increases.
Additionally, we are happy that ReachBio is able to provide not only standard vials of high quality cryopreserved human cells but also flexible customized offerings. This is a great advantage to pharma companies that often have unique requirements for specific types of cells and a strong need for vial-to-vial and lot-to-lot reproducibility. This fits in very well with PELOBiotech’s goal to provide customized solutions to aid our customers’ research.”
About ReachBio Research Labs
ReachBio Research Labs is a life sciences CRO company based out of Seattle, WA USA. We provide primary cell biology based contract research services and products to the drug development and life science research communities worldwide. With expertise encompassing many aspects of primary cell biology and a special focus on blood and bone marrow primary cell systems, we work with customers and clients involved in basic research through multiple areas of pre-clinical and clinical drug development. Our products and services help address our client and customers’ interests in a wide spectrum of areas that include hematology, immunology, toxicology, hematological diseases, immuno-oncology and much more.
For more information, please contact:
PELOBIOTECH GMBH
Dr. Peter Frost | CEO
Christiane Büchsel | Corporate Communications &Marketing
Tel: +49 (0) 89 / 517 286 59 0
Email: info@pelobiotech.com
ReachBio Research Labs
Alix Davis | Marketing Coordinator
T 001 509.309.8453
ReachBio provides research products and contract services (cellPrism® drug development platform) for applications in basic life science research, drug research & development, toxicology and immunology. The company’s main product lines consist of cryopreserved normal human primary cells derived from peripheral blood (including PBMCs), cord blood, bone marrow, as well as ColonyGEL™ methylcellulose-based media for hematopoietic colony-forming cell (CFC) assays.
The extensive ColonyGEL™ semi-solid media product line includes multiple formulations with different cytokine (growth factor) combinations optimized for the growth of a variety of progenitor cells in blood and bone marrow. In the cytokine-optimized, semi-solid environment provided by ColonyGEL™, the different progenitors grow as morphologically distinct three-dimensional colonies that can be identified and scored microscopically. The ColonyGEL™ line-up also includes formulations optimized for different species, including human, mouse, rat, dog and non-human primate. Applications of CFC assays using ColonyGEL™ media include research into normal and abnormal hematological development, leukemia and cancer stem cells, cell therapy, stem cell biology, investigative toxicology, etc.
ReachBio’s line of normal primary human cells includes highly purified cell types from blood that include the various subsets of T lymphocytes, B lymphocytes, natural killer cells and monocytes. It also includes REACHBIO QUALIFIED™ CD34+ stem cells/primitive progenitors purified from cord blood and bone marrow that have been pre-qualified in CFC assays. ReachBio also specializes in providing customized cell isolation services for customers with specific needs such as unique cell types, particular donor background or HLA type, repeat donor cell isolations, and/or customized vial sizes.
“ReachBio Research Labs is extremely happy to have PELOBiotech representing our products and services in Europe,” said Rob Chaney, General Manager and COO at ReachBio. “We have known Peter Frost, one of the founders of PELOBiotech, for many years and have the utmost respect for him and his knowledge of the life science research market within these research-intensive countries. He has already been aiding ReachBio’s sales and business development efforts for our specialized cell biology contract research services in this same territory for the last few years with great results. Having Peter and PELOBiotech now representing our products as well is a great fit and makes perfect sense.”
Said Dr. Peter Frost, CEO of PELOBiotech, “We are delighted to now be distributing ColonyGel™, normal human cell products and promoting the cellPrism® drug development platform. The high quality of these products and services reflects the reputation for quality and value that ReachBio has built regarding both its contract research services and its products. ColonyGEL™ provides researchers performing CFC assays a great alternative to the methylcellulose-based media provided by the leading competitor, which has become quite overpriced through many years of price increases.
Additionally, we are happy that ReachBio is able to provide not only standard vials of high quality cryopreserved human cells but also flexible customized offerings. This is a great advantage to pharma companies that often have unique requirements for specific types of cells and a strong need for vial-to-vial and lot-to-lot reproducibility. This fits in very well with PELOBiotech’s goal to provide customized solutions to aid our customers’ research.”
About ReachBio Research Labs
ReachBio Research Labs is a life sciences CRO company based out of Seattle, WA USA. We provide primary cell biology based contract research services and products to the drug development and life science research communities worldwide. With expertise encompassing many aspects of primary cell biology and a special focus on blood and bone marrow primary cell systems, we work with customers and clients involved in basic research through multiple areas of pre-clinical and clinical drug development. Our products and services help address our client and customers’ interests in a wide spectrum of areas that include hematology, immunology, toxicology, hematological diseases, immuno-oncology and much more.
For more information, please contact:
PELOBIOTECH GMBH
Dr. Peter Frost | CEO
Christiane Büchsel | Corporate Communications &Marketing
Tel: +49 (0) 89 / 517 286 59 0
Email: info@pelobiotech.com
ReachBio Research Labs
Alix Davis | Marketing Coordinator
T 001 509.309.8453
